Matthias Alder - Mar 23, 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Executive Officer, Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
GANX
Transactions as of
Mar 23, 2023
Transactions value $
$0
Form type
4
Date filed
3/27/2023, 05:26 PM
Previous filing
Sep 22, 2022
Next filing
Jul 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +150K $0.00 150K Mar 23, 2023 Common Stock 150K $4.84 Direct F1
transaction GANX Restricted Stock Units Award $0 +75K $0.00 75K Mar 23, 2023 Common Stock 75K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on March 23, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F3 The RSUs shall vest 25% on March 23, 2024 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.